Thursday, Isis Pharmaceuticals Inc. (ISIS) said its third-quarter net loss attributable to Isis Pharmaceuticals Inc. common stockholders was $6.92 million or $0.07 per share compared with a profit of $1.61 million or $0.02 per share in the prior year period. On average, 11 analysts polled by Thomson Reuters expected the company to report a loss of $0.07 per share for the quarter.
Total revenue for the quarter declined to $26.77 million from $29.46 million in the comparable period. Analysts estimated revenues of $31.30 million for the quarter.
For comments and feedback: editorial@rttnews.com